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Abstract: Aspartylglucosaminidase (AGA) is a lysosomal hydrolase that participates in the
breakdown of glycoproteins. Defects in the AGA gene result in a lysosomal storage disorder,
aspartylglucosaminuria (AGU), that manifests mainly as progressive mental retardation. A number of
AGU missense mutations have been identified that result in reduced AGA activity. Human variants
that contain either Ser or Thr in position 149 have been described, but it is unknown if this affects
AGA processing or activity. Here, we have directly compared the Ser149/Thr149 variants of AGA
and show that they do not differ in terms of relative specific activity or processing. Therefore, Thr149
AGA, which is the rare variant, can be considered as a neutral or benign variant. Furthermore, we
have here produced codon-optimized versions of these two variants and show that they are expressed
at significantly higher levels than AGA with the natural codon-usage. Since optimal AGA expression
is of vital importance for both gene therapy and enzyme replacement, our data suggest that use of
codon-optimized AGA may be beneficial for these therapy options.
Keywords: aspartylglucosaminidase; lysosomal storage disorder; aspartylglucosaminuria; lysosomes;
single nucleotide polymorphism; gene therapy
1. Introduction
Aspartylglucosaminidase (AGA, N4-(β-N-Acetylglucosaminyl)-L-Asparaginase, EC 3.5.1.26) is a
lysosomal hydrolase that participates in one of the final steps during the degradation of N-glycosylated
proteins. AGA cleaves the bond between N-acetylglucosamine and asparagine after the polypeptide
backbone has been degraded [1]. AGA is synthesized as a single-chain precursor molecule that soon
after synthesis in the endoplasmic reticulum (ER) homodimerizes and becomes processed into two
pro-α andβ subunits (Figure 1) [2]. This autocatalytic cleavage takes place between the residues Asp205
and Thr206 and is a prerequisite for the activity of the enzyme [3,4]. After transport into lysosomes,
both subunits are C-terminally trimmed. The final active form of AGA is a heterotetramer of two α
and two β or β’ subunits (α2β2) [5]. AGA belongs to the group of so-called N-terminal nucleophile
(NTN) hydrolases, as the free α-amino group of Thr206 is involved in the catalysis as the base, whereas
the OH group of Thr206 functions as a nucleophile during the catalysis [3,6]. The members of the NTN
hydrolase family, which in addition to AGA also include, e.g., the proteasome β subunit and penicillin
acylase, show very little similarity at the amino acid sequence level, but they exhibit a highly similar
folded structure [6].
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Figure 1. Processing and activation of aspartylglucosaminidase (AGA). AGA is synthesized in the ER 
as a 346 amino acid (aa) polypeptide from which 23 residues of the signal peptide are removed. AGA 
contains two N-glycosylation sites at Asn38 and Asn308 [5]. Very soon after synthesis in the ER, two 
AGA precursors homodimerize, inducing an autocatalytic cleavage of both precursors N-terminally 
to Thr206 into 27 kDa pro-α and 17 kDa β subunits. After transport to lysosomes, the pro-α is 
C-terminally cleaved into 24 kDa mature α subunit, whereas processing of the β subunit gives rise to 
the 14 kDa β’ subunit. Neither of these lysosomal processing steps displays an effect on the enzyme 
activity. 
Mutations in the AGA gene result in aspartylglucosaminuria (AGU, OMIM 208400), a lysosomal 
storage disorder that is characterized by progressive loss of intellectual capabilities and some 
skeletal abnormalities [7–9]. AGU patients are born seemingly normal, but the progressive course of 
the disease manifests in, e.g., developmental delay, loss of speech and coarse facial features early in 
childhood [10]. In adulthood, most AGU patients are severely retarded and require special care. 
AGU is a rare disease with an unknown prevalence in most populations, but it is enriched in the 
Finnish population [7,11]. Due to a founder effect, a specific gene defect designated as AGUFin-major is 
found in homozygous form in most Finnish AGU patients, although the parents do not show any 
consanguinity [12,13]. The AGUFin-major mutation, which is a combination of two missense mutations, 
results in an exchange of Cys163 to Ser, abolishing a disulfide bond and destabilizing the AGA 
structure [12,14]. This pathogenic substitution is always combined with a functionally neutral 
Arg161Gln substitution [12,14]. The second most common allele in Finland is a 2 bp deletion called 
AGUFin-minor (NM_000027.3; c.199_200del - p.Glu67fc*3) [15]. Outside Finland, most patients have 
their individual mutations, either in homozygous form, when originating from consanguineous 
marriages, or as compound heterozygous mutations [16–18]. 
AGU mutations result in reduced AGA activity in patient cells. However, depending on the 
mutation type and its consequences on the AGA protein expression, the degree of residual enzyme 
activity may vary considerably [19]. Severe consequences on AGA expression are observed in the 
case of deletions, insertions and splicing mutations, which basically abolish AGA protein expression. 
Very low AGA activities are also detected in the case of nonsense mutations, whereas missense 
mutations show considerable heterogeneity in terms of residual activity [19]. Our recent findings 
have shown that in the case of some point mutations, including AGUFin-major and Thr122Lys, the 
amino acid changes have moderate consequences on the AGA enzyme structure, and these mutant 
forms can be converted into an active form by means of pharmacological chaperones that stabilize 
the enzyme structure [20]. 
A large majority of the AGU mutations, including AGUFin-major, reside outside the active site of 
the enzyme. The Thr122Lys substitution in turn resides in a loop structure close to the interface of 
the two halves of the tetrameric AGA, and is also predicted to cause a local folding defect without 
any severe effect on AGA expression levels [20]. The only AGU mutation that hits the active site of 
AGA is Ser72Pro substitution that causes aberrant processing of the AGA precursor [21]. However, 
Ser72 does not directly participate in the catalysis, but is hydrogen-bonded to the catalytic Thr206 
[3,6]. Interestingly, patients exhibiting this mutation show considerable residual enzyme activity and 
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Mutations in the AGA gene result in aspartylglucosaminuria (AGU, OMIM 208400), a lysosomal
storage disorder that is characterized by progressive loss of intellectual capabilities and some skeletal
abnormalities [7–9]. AGU patients are born seemingly normal, but the progressive course of the
disease manifests in, e.g., developmental delay, loss of speech and coarse facial features early in
childhood [10]. In adulthood, most AGU patients are severely retarded and require special care.
AGU is a rare disease with an unknown prevalence in most populations, but it is enriched in the
Finnish population [7,11]. Due to a founder effect, a specific gene defect designated as AGUFin-major
is found in homozygous form in most Finnish AGU patients, although the parents do not show
any consanguinity [12,13]. The AGUFin-major mutation, which is a combination of two missense
mutations, results in an exchange of Cys163 to Ser, abolishing a disulfide bond and destabilizing the
AGA structure [12,14]. This pathogenic substitution is always combined with a functionally neutral
Arg161Gln substitution [12,14]. The second most common allele in Finland is a 2 bp deletion called
AGUFin-minor (NM_000027.3; c.199_200del - p.Glu67fc*3) [15]. Outside Finland, most patients have their
individual mutations, either in homozygous form, when originating from consanguineous marriages,
or as compound heterozygous mutations [16–18].
AGU mutations result in reduced AGA activity in patient cells. However, depending on the
mutation type and its consequences on the AGA protein expression, the degree of residual enzyme
activity may vary considerably [19]. Severe consequences on AGA expression are observed in the case
of deletions, insertions and splicing mutations, which basically abolish AGA protein expression. Very
low AGA activities are also detected in the case of nonsense mutations, whereas missense mutations
show considerable heterogeneity in terms of residual activity [19]. Our recent findings have shown that
in the case of some point mutations, including AGUFin-major and Thr122Lys, the amino acid changes
have moderate consequences on the AGA enzyme structure, and these mutant forms can be converted
into an active form by means of pharmacological chaperones that stabilize the enzyme structure [20].
A large majority of the AGU mutations, including AGUFin-major, reside outside the active site of
the enzyme. The Thr122Lys substitution in turn resides in a loop structure close to the interface of
the two halves of the tetrameric AGA, and is also predicted to cause a local folding defect without
any severe effect on AGA expression levels [20]. The only AGU mutation that hits the active site of
AGA is Ser72Pro substitution that causes aberrant processing of the AGA precursor [21]. However,
Ser72 does not directly participate in the catalysis, but is hydrogen-bonded to the catalytic Thr206 [3,6].
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Interestingly, patients exhibiting this mutation show considerable residual enzyme activity and appear
to exhibit a milder disease phenotype. These findings show that it is important to understand
the consequences of amino acid substitutions on AGA structure in order to make predictions on
AGA activity.
The human AGA genomic sequence contains a missense single nucleotide polymorphism (SNP)
rs2228119 (NM_000027.3:c.446C>G - p.Thr149Ser) at amino acid position 149, encoding either for
ACT/Thr or AGT/Ser (Figure 2). It is known from various genetic databases that these variants exist,
but so far, it has not been characterized if these variants exhibit any differences in terms of processing or
activity of AGA. Although the Thr149 variant is clearly the rarer one (see Section 2.1), the official AGA
reference sequence NM_000027.3 contains the Thr149 variant. Since most scientists starting to work on
AGA or AGU intuitively would use the reference sequence, it is important to characterize the possible
differences in activity and processing between these two variants. Furthermore, since both gene therapy
approaches and enzyme replacement therapy (ERT) for AGU are currently under development, it
will be of great importance to compare these natural variants in terms of their activity. In addition
to these analyses, we have here tested the expression of the codon-optimized Ser/Thr149 variants of
human AGA. We here show that Ser149 and Thr149 are highly similar in terms of AGA processing
and relative specific activities. However, the Thr149 variant shows a mildly higher expression level in
overexpression systems. The codon-optimized variants of AGA show significantly higher protein and
activity levels upon overexpression in human cells than the natural human variants. Therefore, our
data suggest that codon optimization of AGA may be useful for both gene therapy and ERT.
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Figure 2. Single nucleotide polymorphism rs2228119 (NM_000027.3:c.446C>G - p.(Thr149Ser) results 
in amino acid variation Ser vs. Thr at position 149 (base and amino acid variation in red) of the 
human AGA enzyme. 
2. Results 
2.1. Analysis of the Population Frequency of a Natural AGA Variant  
NM_000027.3:c.446C>G - p.Thr149Ser 
Variant frequency and distribution for NM_000027.3:c.446C>G - p.Thr149Ser were deduced 
from the “1000 genomes project” [22,23] which provides sequence data from 2504 individuals 
originating from five continental regions and 26 different populations. Worldwide, the allele 
frequency for Ser149 was 92%, and 86.3% of all tested subjects were homozygous for the Ser149 
variant, while 11.5% were heterozygous and only 2.2% were homozygous for Thr149. However, 
looking at the global distribution, most Thr149 alleles are found in African populations (allele 
frequency: Ser 71%, Thr 29%), with most of the Thr149 positive probands being heterozygous for 
Ser149 and Thr149. In most European, South and East Asian populations, the Ser149 variant 
accounts for 100% of the alleles. The only exception within Europe is the Iberian population in Spain 
where 0.9% of the sequenced genomes contained the Thr variant in a heterozygous manner. 
Figure 2. Single nucleotide polymorphism rs2228119 (NM_000027.3:c.446C>G - p.(Thr149Ser) results
in amino acid variation Ser vs. Thr at position 149 (base and amino acid variation in red) of the human
AGA enzyme.
2. Results
2.1. Analysis of the Population Frequency of a Natural AGA Variant NM_000027.3:c.446C>G - p.Thr149Ser
Variant frequency and distribution for NM_000027.3:c.446C>G - p.Thr149Ser were deduced from
the “1000 genomes project” [22,23] which provides sequence data from 2504 individuals originating
from five continental regions and 26 different populations. Worldwide, the allele frequency for Ser149
was 92%, and 86.3% of all tested subjects were homozygous for the Ser149 variant, while 11.5% were
heterozygous and only 2.2% were homozygous for Thr149. However, looking at the global distribution,
most Thr149 alleles are found in African populations (allele frequency: Ser 71%, Thr 29%), with most
of the Thr149 positive probands being heterozygous for Ser149 and Thr149. In most European, South
and East Asian populations, the Ser149 variant accounts for 100% of the alleles. The only exception
within Europe is the Iberian population in Spain where 0.9% of the sequenced genomes contained the
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Thr variant in a heterozygous manner. Remarkably, in the Finnish population, which has the world’s
highest AGU prevalence, Ser149 was found to be the sole genotype, which was also confirmed by
the sequencing data of the Exome Aggregation Consortium that contain the genomes of 3307 Finnish
individuals (See http://exac.broadinstitute.org/variant/4-178359960-G-C) [24]. Table 1 summarizes
the distribution of allele frequencies among various populations.
Table 1. Genotype frequency of single nucleotide polymorphism (SNP) rs2228119 in various populations.
Genotype Ser/Ser (%) (n) Ser/Thr (%) (n) Thr/Thr (%) (n)
All Populations Studied 86.3 (2162) 11.5 (288) 2.2 (54)
Europe 99.8 (502) 0.2 (1) - -
Finnish in Finland 100 (99) - - - -
British in England and Scotland 100 (91) - - - -
Iberian populations in Spain 99.1 (106) 0.9 (1) - -
Toscani in Italy 100 (107) - - - -
Utah residents with Northern and 100 (99) - - - -
Western European ancestry
North and South America 94.8 (329) 5.2 (18) - -
Colombian in Medellin 94.7 (89) 5.3 (5) - -
Mexican Ancestry in Los Angeles 100 (64) - - - -
Peruvian in Lima, Peru 98.8 (84) 1.2 (1) - -
Puerto Rican in Puerto Rico 88.5 (92) 11.5 (12) - -
Africa 51.1 (338) 40.7 (269) 8.2 (54)
African Caribean in Barbados 62.5 (60) 32.3 (31) 5.2 (5)
African Ancestry in Southwest US 57.4 (35) 39.3 (24) 3.3 (2)
Esan in Nigeria 46.5 (46) 44.4 (44) 9.1 (9)
Luhya in Webuye, Kenya 46.5 (46) 44.4 (44) 9.1 (9)
Mandinka in Gambia 46.9 (53) 39.8 (45) 13.3 (15)
Mende in Sierra Leone 48.2 (41) 41.2 (35) 10.6 (9)
Yoruba in Ibadan, Nigeria 52.8 (57) 42.6 (46) 4.6 (5)
East Asia 100 (504) - - - -
Chinese Dai in Xishuangbanna 100 (93) - - - -
Han Chinese in Bejing 100 (103) - - - -
Southern Han Chinese 100 (105) - - - -
Japanese in Tokyo, Japan 100 (104) - - - -
Kinh in Ho Chi Minh City, Vietnam 100 (99) - - - -
South Asia 100 (489) - - - -
Bengali in Bangladesh 100 (86) - - - -
Gujarati Indian in Houston, Tx 100 (103) - - - -
Indian Telegu in the UK 100 (102) - - - -
Punjabi in Lahore, Pakistan 100 (96) - - - -
Sri Lankan Tamil in the UK 100 (102) - - - -
2.2. Consequences of the Ser/Thr149 Variants on the Activity and Processing of the AGA Enzyme
To check if the Ser/Thr variants exhibit differences in the activity or processing, the Thr
substitution was introduced into the Ser149 construct in pEXPR-IBA103 [20]. The resulting AGA
variants are thus expressed as Twin-Strep-tagged fusion proteins. We have shown that the tagged
AGA becomes processed into subunits and exhibits normal enzyme activity [20]. The AGA variants
were expressed in HEK93T and HeLa cells and analyzed by Western Blot using anti-AGA antibodies
(Figure 3a–d). Both Ser149 and Thr149 AGA variants became processed into subunits and exhibited
virtually identical patterns of bands in HEK (Figure 3a) and HeLa cells (Figure 3b). The Western
Blot signals were quantified and normalized for the transfection efficiency using cotransfected renilla
luciferase activity as a measure. In both HEK and HeLa cells, the Thr149 variant exhibited a slightly
higher expression level than the Ser149 AGA. Consistent with a higher expression level, the Thr149
also showed a higher level of activity (again normalized for transfection efficiency as above) especially
in HeLa cells (Figure 3e,f). However, the relative specific activities (activity correlated with protein
level) did not significantly differ from each other (Figure 3g,h).
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all constructs; (c,d) Western Blot signals were quantified and normalized to renilla luciferase activity 
to correct for transfection efficiency; (e,f) AGA activity was measured in the same cell lysates as used 
for Western Blot and normalized to renilla luciferase activity; (g,h) AGA activity was normalized to 
AGA protein amount. n ≥ 4, shown as mean ± SD. Statistical analysis by unpaired t-test (c,d,g,h) and 
One-Way ANOVA (e,f). Values of p < 0.05 were considered significant (*) and values of p < 0.01 very 
significant (**). 
2.3. Expression of Codon-Optimized Variants of Ser149 and Thr149 AGA 
AGU is a lysosomal storage disorder for which gene or enzyme replacement therapies (ERT) are 
potential treatment options. In both cases, it is important to obtain a high level of enzyme expression 
and activity in the target tissues. Increased expression of the AGA enzyme might be obtained by 
codon optimization of the constructs used for gene therapy or production of the recombinant 
enzyme for ERT. We thus optimized the codon usage of the human AGA gene and cloned the 
optimized Ser149 and Thr149 variants in pcDNA3 expression vector. In these optimized versions, 
217 of the 346 codons in AGA were exchanged for the optimal ones for human expression. The 
expression and activity of the optimized variants were compared with constructs exhibiting the 
normal human cDNA sequence. Renilla luciferase activity was again used to correct for the 
differences in the transfection efficiencies. A significantly higher protein expression was obtained in 
HEK and HeLa cells for the codon optimized variants, as compared to the respective non-optimized 
ones (Figure 4a–d). Consistently, the normalized enzyme activities were significantly higher with 
Figure 3. Processing and activity of Strep-tagged AGA variants. SNP149-AGA variants with C-terminal
Twin-strep-tag were transiently expressed in (a) HEK293T or (b) HeLa cells. Empty pExpr-IBA103
served as control. Western Blot with anti-AGA antibody shows correct processing of all constructs;
(c,d) Western Blot signals were quantified and normalized to renilla luciferase activity to correct for
transfection efficiency; (e,f) AGA activity was measured in the same cell lysates as used for Western Blot
and normalized to renilla luciferase activity; (g,h) AGA activity was normalized to AGA protein amount.
n ≥ 4, shown as mean ± SD. Statistical analysis by unpaired t-test (c,d,g,h) and One-Way ANOVA (e,f).
Values of p < 0.05 were considered significant (*) and values of p < 0.01 very significant (**).
2.3. Expression of Codon-Optimized Variants of Ser149 and Thr149 AGA
AGU is a lysosomal storage disorder for which gene or enzyme replacement therapies (ERT) are
potential treatment options. In both cases, it is important to obtain a high level of enzyme expression
and activity in the target tissues. Increased expression of the AGA enzyme might be obtained by
codon optimization of the constructs used for gene therapy or production of the recombinant enzyme
for ERT. We thus optimized the codon usage of the human AGA gene and cloned the optimized
Ser149 and Thr149 variants in pcDNA3 expression vector. In these optimized versions, 217 of the
346 codons in AGA were exchanged for the optimal ones for human expression. The expression and
activity of the optimized variants were compared with constructs exhibiting the normal human cDNA
sequence. Renilla luciferase activity was again used to correct for the differences in the transfection
efficiencies. A significantly higher protein expression was obtained in HEK and HeLa cells for the codon
optimized variants, as compared to the respective non-optimized ones (Figure 4a–d). Consistently, the
normalized enzyme activities were significantly higher with the optimized AGA variants (Figure 4e,f).
The optimized Thr149 AGA again showed a tendency to higher expression and activity than the
Int. J. Mol. Sci. 2017, 18, 706 6 of 13
Ser149 counterpart, but this difference was not significant. As with the non-tagged AGA variants, the
relative specific activities of Ser149 and Thr149 AGA were not significantly different from each other
(Figure 4g,h).
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Figure 4. Comparison of processing and activity of the optimized and natural AGA variants. 
SNP149-AGA variants were transiently expressed in (a) HEK293T or (b) HeLa cells. Empty pcDNA3 
plasmid served as a control. Western Blot with anti-AGA antibody shows correct processing of all 
constructs, with higher expression level of codon-optimized constructs; (c,d) Western Blot signals 
were quantified and normalized to renilla luciferase activity to correct for transfection efficiency; (e,f) 
AGA activity was measured in the same cell lysates as used for Western Blot. AGA activity was 
normalized to renilla luciferase activity; (g,h) AGA activity was normalized to AGA protein amount. 
n = 5, shown as mean ± SD. Statistical analysis by One-Way ANOVA. Values of p < 0.01 were 
considered very significant (**) and p < 0.001 extremely significant (***). 
2.4. Expression of AGA Variants in Patient Fibroblasts 
Codon-optimized protein variants may provide a higher level of protein expression and thus 
activity, which would be beneficial for gene therapy approach. However, it has been shown by 
Figure 4. Comparison of processing and activity of the optimized and natural AGA variants.
SNP149-AGA variants were transiently expressed in (a) HEK293T or (b) HeLa cells. Empty pcDNA3
plasmid served as a control. Western Blot with anti-AGA antibody shows correct processing of all
constructs, with higher expression level of codon-optimized constructs; (c,d) Western Blot signals were
quantified and normalized to renilla luciferase activity to correct for transfection efficiency; (e,f) AGA
activity was measured in the same cell lysates as used for Western Blot. AGA activity was normalized
to renilla luciferase activity; (g,h) AGA activity was normalized to AGA protein amount. n = 5, shown
as mean ± SD. Statistical analysis by One-Way ANOVA. Values of p < 0.01 were considered very
significant (**) and p < 0.001 extremely significant (***).
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2.4. Expression of AGA Variants in Patient Fibroblasts
Codon-optimized protein variants may provide a higher level of protein expression and thus
activity, which would be beneficial for gene therapy approach. However, it has been shown by
numerous studies that the use of synonymous codons may alter mRNA structure or even folding
and posttranslational modifications of some proteins (reviewed in [25]). As this may severely
affect the outcome of therapies based on codon-optimized proteins, we tested if the optimized
AGA variants would result in higher enzyme activities when transfected in patient fibroblasts.
The resulting AGA activities were measured and normalized to total protein amount in the lysates.
Due to the low transfections rates, normalization with renilla luciferase (see above) was not feasible.
Our data show that transfection of both wildtype and AGUFin-major fibroblasts with the optimized
AGA variants resulted in significantly higher enzyme activities as compared to the natural variants
(Figure 5). Interestingly, we consistently observed significantly higher AGA activities in the transfected
AGUFin-major fibroblasts than in the respective wildtype ones. This is most likely due to the stabilizing
effect of the cotransfected wildtype AGA (natural or optimized) on the endogenous, mutated
AGUFin-major polypeptide, as we have shown previously [20].
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To show that the transfection with the AGA variants also improves the lysosomal morphology 
in AGU fibroblasts, we stained control-transfected wildtype (WT) and AGUFin-major fibroblasts 
transfected with the AGA variants with Lysotracker to visualize lysosomes (Figure 6). 
Control-transfected AGUFin-major cells showed highly enlarged lysosomes. However, transfection with 
the AGA variant constructs clearly improved lysosomal morphology in these cells. Unfortunately, 
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Figure 5. Activity of the optimized and natural AGA variants in control and patient fibroblasts.
The Thr/Ser149 AGA variants were transiently expressed in wildtype (WT) and AGUFin-major
(AGU-Fin) fibroblasts. The pcDNA3 plasmid without insert served as a control. AGA activity was
measured and normalized to total protein amount of the lysates. Normalized AGA activity in wildtype
fibroblasts transfected with the natural AGA variant Ser149 was set as 100%. n = 4, shown as mean
± SD. Statistical analysis by Two-Way ANOVA. * vs. pcDNA3, # vs. WT. Values of p < 0.05 were
considered significant (* or #) while values of p < 0.01 were considered very significant (**) and p < 0.001
extremely significant (*** or ###).
To show that the transfection with the AGA variants also improves the lysosomal morphology in
AGU fibroblasts, we stained control-transfected wildtype (WT) and AGUFin-major fibroblasts transfected
with the AGA variants with Lysotracker to visualize lysosomes (Figure 6). Control-transfected
AGUFin-major cells showed highly enlarged lysosomes. However, transfection with the AGA variant
constructs clearly improved lysosomal morphology in these cells. Unfortunately, due to the low
transfection efficiency, the data could not be quantified.
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Figure 6. Transfection with the optimized and natural AGA variants in aspartylglucosaminuria (AGU)
patient fibroblasts improves lysosomal morphology. The Thr/Ser149 AGA variants were transiently
expressed in AGUFin-major (AGU-Fin) fibroblasts. Uppermost row: WT and AGU-Fin fibroblasts
transfected with pCDNA3; Middle and lowermost row: AGU-Fin fibroblasts transfected with the
indicated constructs. The cells were stained with Lysotracker-Red and the nuclei were visualized with
4′,6-diamidin-2-phenylindol (DAPI). Scale bar 20 µm.
3. Discussion
We have here characterized the consequences of the genomic variant NM_000027.3:c.446C>G -
p.(Thr149Ser) in the human AGA gene that results in variants of AGA enzyme carrying Ser vs. Thr in
position 149. So far, it has been unclear if the Thr variant represents a benign or pathogenic substitution
that may affect the processing or the activity of the enzyme. In most populations, the Ser variant is
the predominant or even the only one, but especially in some African populations, the Thr variant is
relatively common.
We were able to show that these two variants do not differ from each other in terms of processing
or activity. The Thr149 AGA showed a slightly higher expression level especially in HeLa cells.
The reasons for the higher expression level of Thr149 AGA upon overexpression are not clear, but
this variant might, e.g., exhibit a slightly longer half-life than the Ser149 AGA. However, the relative
specific activities (enzyme activity correlated to AGA protein amount) of Ser149 and Thr149 AGA
were highly similar. This suggests that this variant does not directly affect the enzyme activity, which
is consistent with the fact that the residue 149 does not participate in enzyme catalysis, nor does it
reside within the active site of AGA. Furthermore, the autocatalytic activation by processing into the
subunits appears to take place equally well for both variants, suggesting that the folding is not directly
affected, in accordance with the similar character and size of Thr and Ser residues.
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The observed higher expression level of the Thr149 AGA at the first glimpse suggests that
this variant might be the better option when considering gene therapy or enzyme production for
ERT. However, some caution needs to be called for, since the Thr149 AGA is only observed in
specific populations, such as some African and South-American ones. Therefore, it is possible that
immunological responses against the Thr149 AGA might be observed in patients that naturally carry
the Ser149 variant. In this study, we also generated codon-optimized versions of Ser149 and Thr149
AGA. The optimized AGA enzymes showed the same tendency for a higher expression level of
the Thr149 variant, but no difference in the relative specific activity, as observed for the enzymes
synthesized upon standard codon usage. Thus, we conclude that the Thr149 variant does not differ
from the Ser149 AGA in terms of specific activity, and should thus be considered as a benign variant
that does not exhibit any functional impairment.
The codon-optimized AGA enzyme variants exhibited 2.5- to 5-fold higher expression in HEK
and HeLa cells, as compared to the AGA enzymes with standard codons. These data show that
optimization of the codon usage can indeed result in significantly higher expression of AGA in
heterologous expression systems. Optimization of protein expression is an important aspect when
considering the production of AGA enzyme for ERT. In addition, it is also important that high
expression levels of AGA are obtained by gene therapy approaches to facilitate the spread of the
active enzyme from the cells carrying the gene therapy construct to the neighboring cells and even
to cells farther away in the tissues. However, the potential adverse effects that may result from the
altered codon usage should be considered [25,26]. Numerous studies have addressed the effect of
synonymous or optimized codons on protein expression (excellently reviewed in [25]). Although
such codon substitutions may result in faster protein translation and thus higher expression levels, it
has been shown that they may also adversely affect, e.g., the secondary structure and stability of the
mRNA and thus result in unexpectedly low protein yields. Even more interestingly, “rare” codons
that are translated more slowly appear to be located in areas of the protein that may require more
time for proper folding. Thus, replacing these codons with “fast ones” may impair protein folding
during synthesis and result in a non-functional protein. Thus, it is important to test the effect of codon
optimization on the protein activity before using this strategy for, e.g., gene therapy.
Especially in the case of proteins like AGA that undergo numerous processing steps, care should
also be taken not to overload the expression system. Our data show that upon high degree of AGA
expression, especially with the optimized variants, the AGA precursor form starts to accumulate.
Therefore, it is important to ensure that on the one hand, maximum production of the active AGA
is obtained, but the expression system is not choked by expression levels that are too high, which
would result in production of the inactive AGA precursor. For enzyme production for ERT, expression
systems primed for very high level production should thus be used to obtain a maximum amount of
active AGA enzyme.
We have here tested both the natural and the codon-optimized AGA gene constructs in AGU
patient fibroblasts that are homozygous for AGUFin-major. We showed that expression of both the
natural and the optimized versions of AGA resulted in higher enzyme activities, with the optimized
variants producing the highest activity. Intriguingly, transfection of AGUFin-major fibroblasts resulted
in an AGA activity that was consistently even higher than that obtained with the transfected WT
fibroblasts. Although we cannot completely exclude an effect of different transfection efficiencies
between WT and AGUFin-major cells, we postulate that this positive effect may also be due to the ectopic
WT AGA precursor acting as a “folding aid” for the endogenous AGU polypeptides. The processing of
AGA precursors into the active subunit form requires that two precursor molecules dimerize. We have
earlier shown that cotransfection of WT and AGUFin constructs results in processing and activation of
the mutant AGA precursor that remains as a precursor in the absence of any WT protein [20]. This is
most likely due to the fact that in the cotransfected (or here: WT AGA transfected) cells, the WT
precursors associate with the AGUFin ones and are able to support their folding and processing, thus
resulting in a high degree of improvement of AGA activity in the patient cells. Unfortunately, the
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low sensitivity of the available AGA antibodies did not allow us to test this hypothesis by Western
Blot. However, such a WT-aided processing of the endogenous, mutant AGA precursor would greatly
facilitate gene therapy in AGU patients, as even a lower degree of expression of the WT protein would
result in a relatively high correction of enzyme activity, and most likely also of the lysosomal pathology.
4. Materials and Methods
4.1. Analysis of the Genomic Variant NM_000027.3:c.446C>G - p.Thr149Ser
Worldwide distribution and frequency of the genomic variant NM_000027.3:c.446C>G -
p.Thr149Ser (SNP rs2228119) was analyzed with the “1000 Genomes” browser (http://www.
1000genomes.org/ensembl-browser), which uses genotyping data of 2504 genomes from 26
populations [23].
4.2. Cell Culture
HeLa (human cervix carcinoma cells, (Cat. CCL-2, ATCC, Wesel, Germany), and HEK293T
(human embryonic kidney cells, Cat. CRL-3216, ATCC,) cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM, Gibco, Thermo Fisher Scientific, Karlsruhe, Germany) with high glucose,
supplemented with 10% fetal calf serum (FCS, Gibco), 100 U/mL Penicillin and 100 µg/mL
Streptomycin (Sigma-Aldrich, Taufkirchen, Germany) at 8% CO2 and 37 ◦C. Primary skin fibroblasts
with AGU-Fin mutation were obtained from Coriell Institute of Medical Research (Catalog ID:
GM00568; Camden, NJ, USA). Immortalized normal human skin fibroblasts were as described [27].
Fibroblasts were cultured as described [20].
4.3. Plasmids
AGA Ser149 variant constructs in pcDNA3 (Invitrogen, Thermo Fisher Scientific) and
pExpr-IBA103 (IBA, Göttingen, Germany) vectors were as described [20]. These constructs served as
templates for mutagenesis of Ser149 into Thr149. Codon-optimization and synthesis of the human
AGA sequence carrying the Thr149 was carried out by DNA2.0 (Menlo Park, CA, USA), cloned into
pJ600 (DNA2.0), and subcloned into pcDNA3. The full sequence for the codon-optimized AGA is
available from the authors upon request. The resulting construct served as template for mutagenesis









Twenty-four hours prior to transfection, the cells were seeded onto 12-well plates.
For transfections, 450 ng of the respective AGA expression plasmid and 50 ng of pRL-TK
encoding renilla luciferase for normalization (Promega, Mannheim, Germany) were transfected
using MACSfectin™ (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer’s
protocol. After 24 h, the cells were transferred into 6-well plates and harvested 48 h post-transfection
using 250 µL passive lysis buffer (Promega). Fibroblasts were electroporated using the Neon™
Transfection System (Invitrogen) according to the manufacturer’s instruction. 1 × 106 cells in a
total volume of 100 µL were transfected with 1 µg plasmid (1200 V, 40 ms, 1 pulse). Cells that were
used for lysotracker stainings were cotransfected with 250 ng pEGFP-N1 plasmid (Clontech, Takara,
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Saint-Germain-en-Laye, France) for the detection of transfected cells. Transfected cells were either
seeded into 6 well plates and used for enzyme activity measurements or onto coverslips and used for
staining with Lysotracker as described [20].
4.5. Enzyme Activity Measurements
AGA activity was measured fluorimetrically as described in [20]. For the normalization of
the transfection efficiencies in Hela and HEK cells, renilla luciferase activity was measured with a
Tecan infinite M200 plate reader using 20 µL of 20-fold diluted lysate and 85 µL of renilla juice (PJK,
Kleinblittersdorf, Germany). AGA activity was divided by renilla activity to compensate for the
variations in transfection efficiencies. For the transfected fibroblasts, activities were correlated with the
protein amount.
4.6. Western Blotting Analysis
Equal volumes of non-diluted lysates were analyzed by 15% SDS-polyacrylamide gel
electrophoresis and Western Blot. For antibody staining, the membranes were blocked with 5% non-fat
dry milk in TBST (10 mM Tris, 150 mM NaCl, 0.05% Tween 20) and incubated overnight at 4 ◦C with a
rabbit antiserum against the α and β subunits of AGA [5] in TBST. This was followed by incubation
with HRP-conjugated secondary antibodies in TBST for 1 h at room temperature before development
with Western Blotting Detection Reagents.
4.7. Statistical Analysis
All experiments were performed at least four times. Data are expressed as mean ± SD. Statistical
comparisons between groups were made using Student’s t-tests, One-Way or Two-Way ANOVA, as
appropriate (GraphPad Prism 5, GrapdPad Software Inc., La jolla, CA, USA). Western Blot bands were
quantified by scanning densitometry using Quantity One Software (version 4.6, Bio-Rad, Munich,
Germany) and normalized against the Renilla luciferase activity measured from the same lysates
(see above). Values of p < 0.05 were considered significant (*) while values of p < 0.01 were considered
very significant (**) and p < 0.001 extremely significant (***).
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